Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma ranks among the most lethal of human malignancies. Here, we assess the cooperative interactions of two signature mutations in mice engineered to sustain pancreas-specific Cre-mediated activation of a mutant Kras allele ( Kras G12D ) and deletion of a conditional Ink4a/Arf tumor suppressor allele. The phenotypic impact of Kras G12D alone was limited primarily to the development of focal premalignant ductal lesions, termed pancreatic intraepithelial neoplasias (PanINs), whereas the sole inactivation of Ink4a/Arf failed to produce any neoplastic lesions in the pancreas. In combination, Kras G12D expression and Ink4a/Arf deficiency resulted in an earlier appearance of PanIN lesions and these neoplasms progressed rapidly to highly invasive and metastatic cancers, resulting in death in all cases by 11 weeks. The evolution of these tumors bears striking resemblance to the human disease, possessing a proliferative stromal component and ductal lesions with a propensity to advance to a poorly differentiated state. These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma. This faithful mouse model may permit the systematic analysis of genetic lesions implicated in the human disease and serve as a platform for the identification of early disease markers and for the efficient testing of novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These KRAS mutations are also found in the early stages of pancreatic ductal adenocarcinoma, preceding the appearance of senescence markers such as p53, CDKN2A and SMAD4196.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [196]
Experimental — accuracy not yet measuredIn the citing paper
“In a mouse model, CDKN2A loss accelerated KRASG12D-driven tumor growth54.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [54]
In the citing paper
“GEMMs with compound mutations that combine Kras mutation with the inactivation of tumor suppressor genes Cdkn2a and Tp53, or with the inactivation of the TGFβ-SMAD4 signaling pathway in the pancreas develop invasive and metastatic PDAC (74–76), thus validating the role of these tumor suppressor pathways in PDAC progression (4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [74]
In the citing paper
“combined expression of oncogenic Kras coupled with the deletion or loss of function of Trp53, Cdkn2a, or Smad4 in the pancreas of mice readily leads to invasive PDAC29–32.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 2×
“…in line with the high degree of coincident mutations of these genes in human cancers and the role of Ink4a/Arf loss in facilitating the oncogenicity of activated Hras in vitro and in vivo (Serrano et al. 1996, 1997; Chin et al. 1997; Kamijo et al. 1997; Rozenblum et al. 1997; Ruas and Peters 1998).”
BackgroundSelf-citationTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“Although ARF is a known activator of the p53 pathway (Kamijo et al. 1998; Pomerantz et al. 1998; Stott et al. 1998; Zhang et al. 1998) and its loss clearly attenuates the function of that critical tumor suppressor, more recent studies have demonstrated that ARF has p53-independent…”
BackgroundSelf-citationGu, G., Dubauskaite, J., & Melton, D. A. (2002) · Development · doi:10.1242/dev.129.10.2447 · Cited by 1,518
Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
Warshaw, A. L., & Castillo, C. F.-D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202133260706 · Cited by 1,198
Stott, F. J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,167
Research works printed but not linked: 17
- 2003, Cancer Res., 63, 2005
- 1976, Cancer Res., 36, 2690
- 1990, Mol. Cell. Biol., 10, 1779
- 1992, Am. J. Pathol., 140, 1237
- 2003, Cancer Res., 63, 2016
- 2001, Cancer Res., 61, 4923
- 1994, Am. J. Pathol., 145, 1547
- 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O · doi:10.1002/(sici)1098-2264(200004)27:4<358::aid-gcc4>3.0.co;2-o
- 10.1002/(SICI)1097-0142(19990415)85:8<1703::AID-CNCR9>3.0.CO;2-R · DOI
- 2001, Cancer J., 7, 242
- 1997, Cancer Res., 57, 2140
- 1997, Cancer Res., 57, 1731
- 1998, Biochim. Biophys. Acta, 1378, F115
- 1998, Cancer Res., 58, 4740
- 2000, Cancer Res., 60, 2002
- 1986, Jpn. J. Cancer Res., 77, 370
- 1994, Am. J. Pathol., 145, 671
Cited by
Items 101–200 of 999
Philip, P. A., Mooney, M., Jaffe, D., Eckhardt, G., Moore, M., Meropol, N., Emens, L., O'Reilly, E., Korc, M., Ellis, L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9022 · Cited by 240
Carrière, C., Young, A. L., Gunn, J. R., Longnecker, D. S., & Korc, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.03.068 · Cited by 237
“Immunostaining procedures were as described previously [12].”
Molecular Pathogenesis of Pancreatic Cancer
Grant, T. J., Hua, K., & Singh, A. (2016) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.09.008 · Cited by 237
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 237
Oshima, M., Okano, K., Muraki, S., Haba, R., Maeba, T., Suzuki, Y., & Yachida, S. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182827a65 · Cited by 236
Pancreatic ductal cells in development, regeneration, and neoplasia
Reichert, M., & Rustgi, A. K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57131 · Cited by 235
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 235
Obesity and cancer pathogenesis
Berger, N. A. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12416 · Cited by 231
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A., Chan-Seng-Yue, M., Wilson, G., Grant, R. C., Merico, D., Lungu, I., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.010 · Cited by 231
TP63-mediated enhancer reprogramming drives the squamous subtype of pancreatic ductal adenocarcinoma
Somerville, T. D. D., Xu, Y., Miyabayashi, K., Tiriac, H., Cleary, C. R., Maia-Silva, D., Milazzo, J. P., Tuveson, D. A., & Vakoc, C. R. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.051 · Cited by 225
“This malignancy is typically initiated by an activating mutation in KRAS in a ductal or an acinar cell of the pancreas, which collaborates with the loss of tumor suppressor genes to drive PDA progression (Aguirre et al., 2003; Hingorani et al., 2003, 2005).”
BackgroundSelf-citationSonic hedgehog acts at multiple stages during pancreatic tumorigenesis
Morton, J. P., Mongeau, M. E., Klimstra, D. S., Morris, J. P., Lee, Y. C., Kawaguchi, Y., Wright, C. V. E., Hebrok, M., & Lewis, B. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701158104 · Cited by 223
Ying, H., Elpek, K. G., Vinjamoori, A., Zimmerman, S. M., Chu, G. C., Yan, H., Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0031 · Cited by 223
Self-citationDannenberg, J.-H., David, G., Zhong, S., van der Torre, J., Wong, W. H., & DePinho, R. A. (2005) · Genes & Development · doi:10.1101/gad.1286905 · Cited by 221
“pression cassette (Aguirre et al. 2003) and a 3 loxP site.”
BackgroundSelf-citationDey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0297 · Cited by 213
“Primary mouse cell lines were established in the laboratory (AK-B6, AK192, HY6468, PJAK4217, PJAK4298) as described previously (34) and were routinely cultured in RPMI 1640 (Invitrogen) 10% FBS (Invitrogen).”
MethodSelf-citationPancreatic Cancer Metabolism: Breaking It Down to Build It Back Up
Perera, R. M., & Bardeesy, N. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0671 · Cited by 217
Self-citationAssessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. K., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215
“In this study, we use two previously established and characterized GEMMs that are driven by the same conditional mutant Kras allele to examine standard-of-care agents both alone and in combination with therapeutics targeting epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF): Kras LS…”
MethodYes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma
Murakami, S., Shahbazian, D., Surana, R., Zhang, W., Chen, H., Graham, G. T., White, S. M., Weiner, L. M., & Yi, C. (2017) · Oncogene · doi:10.1038/onc.2016.288 · Cited by 215
“Various genetically engineered mouse models have been developed to reproduce the progression of human PDAC (Aguirre et al 2003, Brembeck et al 2003, Grippo et al 2003, Hingorani et al 2003, Tuveson et al 2006).”
BackgroundSyndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer
Yao, W., Rose, J. L., Wang, W., Seth, S., Jiang, H., Taguchi, A., Liu, J., Yan, L., Kapoor, A., Hou, P., et al. (2019) · Nature · doi:10.1038/s41586-019-1062-1 · Cited by 214
Self-citationAcinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia
Zhu, L., Shi, G., Schmidt, C. M., Hruban, R. H., & Konieczny, S. F. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061176 · Cited by 212
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma
Mann, K. M., Ward, J. M., Yew, C. C. K., Kovochich, A., Dawson, D. W., Black, M. A., Brett, B. T., Sheetz, T. E., Dupuy, A. J., Initiative, A. P. C. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202490109 · Cited by 213
Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy
Marinković, M., Šprung, M., Buljubašić, M., & Novak, I. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8023821 · Cited by 211
“Activating KRAS mutations were found in over 90% of PDAC [100] that further confirms the critical role of KRAS in PDAC carcinogenesis that came frommouse models [101, 102].”
BackgroundCanonical Wnt Signaling Is Required for Pancreatic Carcinogenesis
Zhang, Y., Morris, J. P., Yan, W., Schofield, H. K., Gurney, A., Simeone, D. M., Millar, S. E., Hoey, T., Hebrok, M., & Pasca di Magliano, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4384 · Cited by 208
“1B) when KC and KDC mice only have rare PanINs (7, 30); thus, in this experiment, Dkk1 expression preceded PanIN formation.”
Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis
Eckert, L. B., Repasky, G. A., Ülkü, A. S., McFall, A., Zhou, H., Sartor, C. I., & Der, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0396 · Cited by 207
Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression
Shields, M. A., Dangi-Garimella, S., Redig, A. J., & Munshi, H. G. (2012) · Biochemical Journal · doi:10.1042/bj20111240 · Cited by 205
RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma
Whittle, M. C., Izeradjene, K., Rani, P. G., Feng, L., Carlson, M. A., DelGiorno, K. E., Wood, L. D., Goggins, M., Hruban, R. H., Chang, A. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.048 · Cited by 204
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans
Ochi, A., Graffeo, C. S., Zambirinis, C. P., Rehman, A., Hackman, M., Fallon, N., Barilla, R. M., Henning, J. R., Jamal, M., Rao, R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63606 · Cited by 199
“…mutations in both Kras and Trp53 (gift of M. Philips, New York University, New York, New York, USA), and PDX1-Cre;Kras G12D ;Ink4a/Arf fl/fl mice (66), with Kras G12D expression in combination with Ink4a/Arf deficiency (gift of G. David, New York University, New York, New York, USA), were used…”
Inactivation of Smad4 Accelerates KrasG12D-Mediated Pancreatic Neoplasia
Kojima, K., Vickers, S. M., Adsay, N. V., Jhala, N. C., Kim, H.-G., Schoeb, T. R., Grizzle, W. E., & Klug, C. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4167 · Cited by 197
“Analysis of mice where a Pdx1-Cre transgene was used to activate expression of a constitutively active allele of Kras (Kras) in the ductal epithelium showed the full spectrum of preinvasive PanIN-like lesions (mPanIN), which supports the model that Kras activation is a critical initiating step in progression to PDAC (…”
BackgroundRas Activity Levels Control the Development of Pancreatic Diseases
Ji, B., Tsou, L., Wang, H., Gaiser, S., Chang, D. Z., Daniluk, J., Bi, Y., Grote, T., Longnecker, D. S., & Logsdon, C. D. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.05.052 · Cited by 194
Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer
Feldmann, G., Habbe, N., Dhara, S., Bisht, S., Alvarez, H., Fendrich, V, Beaty, R., Mullendore, M., Karikari, C., Bardeesy, N., et al. (2008) · Gut · doi:10.1136/gut.2007.148189 · Cited by 193
“Primer sequences are listed in table 2.(9)”
BackgroundInfluentialSelf-citationvon Figura, G., Fukuda, A., Roy, N., Liku, M. E., Morris IV, J. P., Kim, G. E., Russ, H. A., Firpo, M. A., Mulvihill, S. J., Dawson, D. W., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2916 · Cited by 190
Patra, K. C., Kato, Y., Mizukami, Y., Widholz, S., Boukhali, M., Revenco, I., Grossman, E. A., Ji, F., Sadreyev, R. I., Liss, A. S., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0122-3 · Cited by 192
Self-citationKRAS-related proteins in pancreatic cancer
Mann, K. M., Ying, H., Juan, J., Jenkins, N. A., & Copeland, N. G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.003 · Cited by 187
“GEMM models that combine oncogenic Kras mutation with conditional loss of one or more of these four genes develop rapid pancreatic cancer with metastasis to the liver, peritoneum and lung (Aguirre et al., 2003; Hingorani et al., 2005; Izeradjene et al., 2007; Kojima et al., 2007; Feldmann et al., 2010).”
BackgroundInfluentialMetastatic pancreatic cancer is dependent on oncogenic Kras in mice
Collins, M. A., Brisset, J.-C., Zhang, Y., Bednar, F., Pierre, J., Heist, K. A., Galbán, C. J., Galbán, S., & di Magliano, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049707 · Cited by 178
Basics of TGF-ß and Pancreatic Cancer
Truty, M. J., & Urrutia, R. (2007) · Pancreatology · doi:10.1159/000108959 · Cited by 185
“Such mice eventually developed pancreatic adenocarcinoma, thus establishing PanINs as true precursors to invasive disease. However, oncogene activation such as Kras mutations alone is not sufficient for full malignant development. It is the incorporation of mutations or alterations in tumor-suppressor alleles which sy…”
BackgroundKoorstra, J.-B. M., Hustinx, S. R., Offerhaus, G. J. A., & Maitra, A. (2008) · Pancreatology · doi:10.1159/000123838 · Cited by 183
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
“Experiments in genetically altered mice have however demonstrated that KRas activation is alone insufficient for PDAC development: CRE-dependent activation of the endogenously expressed lsl-KRasG12D allele (5) alone gives rise predominantly to low-grade pancreatic intraepithelial neoplasms (PanINs), a subset of which…”
BackgroundGenetically engineered mouse models of pancreatic adenocarcinoma
Guerra, C., & Barbacid, M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.002 · Cited by 179
“Yet, loss of these tumor suppressors greatly synergizes with KRas oncogenes leading to the rapid induction of PDAC tumors as well as anaplastic sarcomatoid tumors (Aguirre et al., 2003; Guerra et al., 2011).”
BackgroundA p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer
Mello, S. S., Valente, L. J., Raj, N., Seoane, J. A., Flowers, B. M., McClendon, J., Bieging-Rolett, K. T., Lee, J., Ivanochko, D., Kozak, M. M., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.007 · Cited by 179
“Studies using genetically engineered mouse models have demonstrated that Kras activation along with mutation of one copy of any of these tumor suppressor genes is sufficient to drive PDAC development (Aguirre et al., 2003; Bardeesy et al., 2006a, 2006b; Hingorani et al., 2005; Izeradjene et al., 2007).”
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs
Tzatsos, A., Paskaleva, P., Ferrari, F., Deshpande, V., Stoykova, S., Contino, G., Wong, K.-K., Lan, F., Trojer, P., Park, P. J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64535 · Cited by 178
Self-citationHarnessing metabolic dependencies in pancreatic cancers
Encarnación-Rosado, J., & Kimmelman, A. C. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00431-7 · Cited by 174
Selective alanine transporter utilization creates a targetable metabolic niche in pancreatic cancer
Parker, S. J., Amendola, C. R., Hollinshead, K. E. R., Yu, Q., Yamamoto, K., Encarnación-Rosado, J., Rose, R. E., LaRue, M. M., Sohn, A. S. W., Biancur, D. E., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0959 · Cited by 175
“Primary murine PDAC cell lines 6 (HY19636, MPDAC4, and HY15549) were isolated from KPC tumors using established 7 protocols (63).”
MethodAdvances in imaging mouse tumour models in vivo
Lyons, S. K. (2005) · The Journal of Pathology · doi:10.1002/path.1697 · Cited by 174
“Aspects that underlie the molecular basis of human cancer are also well addressed and mouse models have provided an essential means with which to elucidate the involvement and in vivo effects of various genetic lesions in tumourigenesis, tumour progression, and metastasis [1–5].”
BackgroundWhat We Have Learned About Pancreatic Cancer From Mouse Models
Pérez–Mancera, P. A., Guerra, C., Barbacid, M., & Tuveson, D. A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.002 · Cited by 172
Self-citationLiu, S., & Leach, S. D. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130330 · Cited by 171
Combination Therapies with CDK4/6 Inhibitors to Treat KRAS- Mutant Pancreatic Cancer
Goodwin, C. M., Waters, A. M., Klomp, J. E., Javaid, S., Bryant, K. L., Stalnecker, C. A., Drizyte-Miller, K., Papke, B., Yang, R., Amparo, A. M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-0391 · Cited by 168
The acinar differentiation determinant PTF1A inhibits initiation of pancreatic ductal adenocarcinoma
Krah, N. M., De La O, J.-P., Swift, G. H., Hoang, C. Q., Willet, S. G., Chen Pan, F., Cash, G. M., Bronner, M. P., Wright, C. V., MacDonald, R. J., et al. (2015) · eLife · doi:10.7554/elife.07125 · Cited by 166
“…or to model in human tissue (Boj et al., 2015), much has been learned from the ‘KC’ mouse model in which a Cre-inducible oncogenic Kras allele (KrasLSL-G12D) causes focal PanIN formation when activated universally in the pancreas (Aguirre et al., 2003; Hingorani et al., 2003; Murtaugh, 2014).”
BackgroundMouse models of pancreatic cancer
Herreros-Villanueva, M. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i12.1286 · Cited by 164
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Bournet, B., Buscail, C., Muscari, F., Cordelier, P., & Buscail, L. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.012 · Cited by 164
Plentz, R., Park, J., Rhim, A. D., Abravanel, D., Hezel, A. F., Sharma, S. V., Gurumurthy, S., Deshpande, V., Kenific, C., Settleman, J., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.008 · Cited by 163
Self-citationSpatial Regulation of RhoA Activity during Pancreatic Cancer Cell Invasion Driven by Mutant p53
Timpson, P., McGhee, E. J., Morton, J. P., von Kriegsheim, A., Schwarz, J. P., Karim, S. A., Doyle, B., Quinn, J. A., Carragher, N. O., Edward, M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2267 · Cited by 162
“Initiating KRAS mutations occur in approximately 90% of human PDACs (18-20) while TP53 mutations arise in 50-75% of human pancreatic cancers (21).”
InfluentialPTEN Loss Accelerates Kras G12D -Induced Pancreatic Cancer Development
Hill, R., Calvopina, J. H., Kim, C., Wang, Y., Dawson, D. W., Donahue, T. R., Dry, S., & Wu, H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1649 · Cited by 161
“Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.”
BackgroundMethodInfluentialTumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer
Hou, P., Kapoor, A., Zhang, Q., Li, J., Wu, C.-J., Li, J., Lan, Z., Tang, M., Ma, X., Ackroyd, J. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0597 · Cited by 154
“In mouse 59 models, KRAS* serves as a tumor initiating event and, together with loss of tumor suppressor 60 genes, can drive advanced disease that recapitulates well the biology of human PDAC (3, 4).”
BackgroundSelf-citationKim, M. P., Li, X., Deng, J., Zhang, Y., Dai, B., Allton, K. L., Hughes, T. G., Siangco, C., Augustine, J. J., Kang, Y., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1228 · Cited by 153
Dawson, D. W., Hertzer, K., Moro, A., Donald, G., Chang, H.-H., Go, V. L., Pandol, S. J., Lugea, A., Gukovskaya, A. S., Li, G., et al. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0065 · Cited by 153
“The presence of another mutation, for example, in the Trp53 or Ink4a/Arf tumor suppressor genes, greatly accelerates PaCa development (7, 8).”
BackgroundSiveke, J. T., Einwächter, H., Sipos, B., Lubeseder–Martellato, C., Klöppel, G., & Schmid, R. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.002 · Cited by 170
Vasen, H. F. A., Wasser, M., van Mil, A., Tollenaar, R. A., Konstantinovski, M., Gruis, N. A., Bergman, W., Hes, F. J., Hommes, D. W., Offerhaus, G. J. A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.048 · Cited by 152
The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance
Biancur, D. E., & Kimmelman, A. C. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.04.011 · Cited by 152
“Consistent with this observation, mouse models of pancreatic cancer driven by a pancreas-specific Cre-deleter and a latent knock-in allele of oncogenic Kras (LSL-KrasG12D;PdxCre) have long latency or require the loss of tumor suppressor genes (TP53, CDKN2A, SMAD4, and others) to develop a tumor [5, 6].”
BackgroundHashimoto, S., Furukawa, S., Hashimoto, A., Tsutaho, A., Fukao, A., Sakamura, Y., Parajuli, G., Onodera, Y., Otsuka, Y., Handa, H., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901765116 · Cited by 149
Critical role of NF-κB in pancreatic cancer
Prabhu, L., Mundade, R., Korc, M., Loehrer, P. J., & Lu, T. (2014) · Oncotarget · doi:10.18632/oncotarget.2624 · Cited by 148
“PanIN is a crucial feature of PDAC initiation in humans and GEMMs, and PanIN progression to PDAC is accelerated by loss of tumor suppressor genes such as p53, Cdkn2A (cyclin-dependent kinase inhibitor 2A), Smad4 (mothers against decapentaplegic homolog 4), Pten (phosphatase and tensin homolog), or Rb (retinoblastoma p…”
BackgroundPark, S. W., Davison, J. M., Rhee, J. M., Hruban, R. H., Maitra, A., & Leach, S. D. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.084 · Cited by 159
AKT1 Activation Promotes Development of Melanoma Metastases
Cho, J. H., Robinson, J. P., Arave, R. A., Burnett, W. J., Kircher, D. A., Chen, G., Davies, M. A., Grossmann, A. H., VanBrocklin, M. W., McMahon, M., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.057 · Cited by 156
“The Cdkn2alox allele expresses normal INK4A and ARF prior to Cre-mediated recombination after which expression of both p16INK4A and p19ARF is extinguished (Aguirre et al., 2003).”
Alcohol and Cancer: Mechanisms and Therapies
Ratna, A., & Mandrekar, P. (2017) · Biomolecules · doi:10.3390/biom7030061 · Cited by 174
Stabilization of β-Catenin Induces Pancreas Tumor Formation
Heiser, P. W., Cano, D. A., Landsman, L., Kim, G. E., Kench, J. G., Klimstra, D. S., Taketo, M. M., Biankin, A. V., & Hebrok, M. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.089 · Cited by 145
DuFort, C. C., DelGiorno, K. E., & Hingorani, S. R. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.040 · Cited by 144
mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation
Damsky, W., Micevic, G., Meeth, K., Muthusamy, V., Curley, D. P., Santhanakrishnan, M., Erdelyi, I., Platt, J. T., Huang, L., Theodosakis, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.014 · Cited by 142
“, 2009) were crossed with Cdkn2a mice (Aguirre et al., 2003).”
BackgroundSelf-citationDeregulation of FoxM1b leads to tumour metastasis
Park, H. J., Gusarova, G. A., Wang, Z., Carr, J. R., Li, J., Kim, K., Qiu, J., Park, Y., Williamson, P. R., Hay, N., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000107 · Cited by 154
Genetically Engineered Mouse Models of Pancreatic Cancer
Westphalen, C. B., & Olive, K. P. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31827ab4c4 · Cited by 139
“In 2003, the groups of David Tuveson and Ronald DePinho each took advantage of the K-ras mouse to generate new models of PDAC that recapitulate the stepwise development of cancer seen in humans.(15,16) During development, all pancreatic cells are derived from panYpancreatic progenitors labeled by the transcription fac…”
BackgroundMethodCell of origin affects tumour development and phenotype in pancreatic ductal adenocarcinoma
Lee, A. Y. L., Dubois, C. L., Sarai, K., Zarei, S., Schaeffer, D. F., Sander, M., & Kopp, J. L. (2019) · Gut · doi:10.1136/gutjnl-2017-314426 · Cited by 139
The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia
Carrière, C., Seeley, E. S., Goetze, T., Longnecker, D. S., & Korc, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701117104 · Cited by 138
Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation
Zeng, H., Jorapur, A., Shain, A. H., Lang, U. E., Torres, R., Zhang, Y., McNeal, A. S., Botton, T., Lin, J., Donne, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.014 · Cited by 137
“Previous reports have connected CDKN2A loss with metastatic dissemination in mouse model systems, but the mechanism has been attributed to indirect effects of p16INK4A on cell cycle regulation or p14ARF on p53mediated apoptosis(Ackermann et al., 2005; Aguirre et al., 2003; Krimpenfort et al., 2001; Pavey et al., 2002).”
BackgroundTuveson, D. A., Zhu, L., Gopinathan, A., Willis, N. A., Kachatrian, L., Grochow, R., Pin, C. L., Mitin, N. Y., Taparowsky, E. J., Gimotty, P. A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2305 · Cited by 137
Self-citationEZH2 couples pancreatic regeneration to neoplastic progression
Mallen-St. Clair, J., Soydaner-Azeloglu, R., Lee, K. E., Taylor, L., Livanos, A., Pylayeva-Gupta, Y., Miller, G., Margueron, R., Reinberg, D., & Bar-Sagi, D. (2012) · Genes & Development · doi:10.1101/gad.181800.111 · Cited by 135
“However, as a reference, p48-Cre;Kras mice develop advanced mPanINs with amean latency of 6mo (Aguirre et al. 2003).”
BackgroundA Conditional Mouse Model for Malignant Mesothelioma
Jongsma, J., van Montfort, E. H. N., Vooijs, M., Zevenhoven, J., Krimpenfort, P., van der Valk, M., van de Vijver, M. J., & Berns, A. J. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.030 · Cited by 138
GEMMs as preclinical models for testing pancreatic cancer therapies
Gopinathan, A., Morton, J. P., Jodrell, D. I., & Sansom, O. J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.021055 · Cited by 133
“…of metastasis; histologically, there is a higher number of sarcomatoid, undifferentiated tumours in models with disruption of the Cdkn2a locus Aguirre et al., 2003; Bardeesy et al., 2006 KrasG12D; Ptenflox; Cre Oncogenic Kras; heterozygous Pten loss Dramatically accelerates PanIN and…”
Nolte, T., Brander-Weber, P., Dangler, C. A., Deschl, U., Elwell, M. R., Greaves, P., Hailey, R., Leach, M. W., Pandiri, A. R., Rogers, A. B., et al. (2016) · Journal of Toxicologic Pathology · doi:10.1293/tox.29.1s · Cited by 149
“2003; Aguirre et al.”
BackgroundDetection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies
Sharma, R., Huang, X., Brekken, R. A., & Schroit, A. J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.183 · Cited by 137
“For the KIC model, histologically confirmed high-grade adenocarcinomas generally appear at 35 days of age (Aguirre et al, 2003) where blood exosome levels were three-fold higher than the levels of age-matched littermate controls (260 vs 85 pg).”
BackgroundMethodStromal protein βig-h3 reprogrammes tumour microenvironment in pancreatic cancer
Goehrig, D., Nigri, J., Samain, R., Wu, Z., Cappello, P., Gabiane, G., Zhang, X., Zhao, Y., Kim, I.-S., Chanal, M., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317570 · Cited by 131
“21 23 49 OT1/Rag2 KO transgenic mice expressing the T cell receptor were used as the source of the CD8 + T cells that were used in the in vitro experiments.”
MethodRebuilding cancer metastasis in the mouse
Saxena, M., & Christofori, G. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.009 · Cited by 132
MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2
Wang, X., Shi, Z., Wang, X.-R., Cao, L., Wang, Y., Zhang, J., Yin, Y., Luo, H., Kang, C., Liu, N., et al. (2011) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-011-1114-x · Cited by 138
“…frequent genetic events observed in tumor patients, and the activation of the K-ras pathway has been well-documented in various tumor types, such as lung cancer (Santos et al. 1984), pancreatic cancer (Aguirre et al. 2003), colon cancer (Janssen et al. 2006), and breast cancer (Forbes et al. 2006).”
BackgroundA Mouse Model of Rhabdomyosarcoma Originating from the Adipocyte Lineage
Hatley, M. E., Tang, W., Garcia, M. R., Finkelstein, D., Millay, D. P., Liu, N., Graff, J. M., Galindo, R. L., & Olson, E. N. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.004 · Cited by 149
“To test for potential cooperativity between Cdkn2a and hedgehog-driven ERMS, we intercrossed a conditional Cdkn2a Flox allele into our model (Aguirre et al., 2003). aP2-Cre;Cdkn2a Flox/Flox mice did not develop ERMS, whereas deletion of Cdkn2a in aP2-Cre; Smo M2/+ ;Cdkn2a Flox/Flox mice triggered…”
MethodInfluentialMouse models in oncogenesis and cancer therapy
Céspedes, M. V., Casanova, I., Parreño, M., & Mangues, R. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0177-7 · Cited by 146
Hu, C.-M., Tien, S.-C., Hsieh, P.-K., Jeng, Y.-M., Chang, M.-C., Chang, Y.-T., Chen, Y.-J., Chen, Y.-J., Lee, E. Y.-H. P., & Lee, W.-H. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.005 · Cited by 123
Hamidi, T., Algül, H., Cano, C. E., Sandi, M. J., Molejon, M. I., Riemann, M., Calvo, E. L., Lomberk, G., Dagorn, J.-C., Weih, F., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60144 · Cited by 130
“As previously reported (26–28), we observed that the pancreas of Kras G12D mice develop numerous PanIN lesions from 13 weeks of age (Figure 1A).”
InfluentialExpression of S100P and Its Novel Binding Partner S100PBPR in Early Pancreatic Cancer
Dowen, S. E., Crnogorac‐Jurcevic, T., Gangeswaran, R., Hansen, M., Eloranta, J. J., Bhakta, V., Brentnall, T. A., Lüttges, J., Klöppel, G., & Lemoine, N. R. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62234-1 · Cited by 135
Lesina, M., Wörmann, S. M., Morton, J., Diakopoulos, K. N., Korneeva, O., Wimmer, M., Einwächter, H., Sperveslage, J., Demir, I. E., Kehl, T., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86477 · Cited by 128
The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis
Rajurkar, M., De Jesus-Monge, W. E., Driscoll, D. R., Appleman, V. A., Huang, H., Cotton, J. L., Klimstra, D. S., Zhu, L. J., Simin, K., Xu, L., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114168109 · Cited by 127
“Despite the frequent formation of advanced lesions at an early age, we did not observe invasive or metastatic PDAC in the Ptf1a-Cre;LSL-Kras;R26-Gli1 mice that survived to 10 mo of age, suggesting the requirement for additional oncogenic alterations, possibly loss of p53 or p16 function (6, 7).”
BackgroundMouse models for studying angiogenesis and lymphangiogenesis in cancer
Eklund, L., Bry, M., & Alitalo, K. K. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.007 · Cited by 150
Keklikoglou, I., Hosaka, K., Bender, C., Bott, A., Koerner, C., Mitra, D., Will, R., Woerner, A., Muenstermann, E., Wilhelm, H., et al. (2015) · Oncogene · doi:10.1038/onc.2014.408 · Cited by 108
Mutant KRAS in the initiation of pancreatic cancer
Deramaudt, T. B., & Rustgi, A. K. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.08.003 · Cited by 145
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119
Self-citationInactivation of TIF1γ Cooperates with KrasG12D to Induce Cystic Tumors of the Pancreas
Vincent, D. F., Yan, K.-P., Treilleux, I., Gay, F., Arfi, V., Kaniewsky, B., Marie, J. C., Lepinasse, F., Martel, S., Goddard-Leon, S., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000575 · Cited by 122
“Ink4A/Arf [12], LSL-Kras [8,43–45] and Pdx1-Cre [34] mouse strains done by others were previously described.”
MethodInfluentialSelf-citationGenome profiling of pancreatic adenocarcinoma
Birnbaum, D. J., Adélaïde, J., Mamessier, E., Finetti, P., Lagarde, A., Monges, G., Viret, F., Gonçalvès, A., Turrini, O., Delpero, J., et al. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20870 · Cited by 122
“In genetically engineered mouse models of pancreatic cancer KRAS mutants act in concert with inactivation of TP53 (Hingorani et al., 2005), CDKN2A (Aguirre et al., 2003; Bardeesy et al., 2006), TGFBR2 (Ijichi et al., 2006), SMAD4 (Kojima et al., 2007), TRIM33 (Vincent et al., 2009), and STK11/LKB1…”
BackgroundInfluentialPancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development?
Rooman, I., & Real, F. X. (2012) · Gut · doi:10.1136/gut.2010.235804 · Cited by 120
“In general, mutant K-Ras is activated in all pancreatic cells by targeting Cre recombinase to pancreatic progenitors at the time of pancreas formation (about E9) using the regulatory elements of pancreatic and duodenal homeobox 1 (Pdx1) or pancreatic transcription factor 1a (Ptf1a), two genes required for pancreas for…”
BackgroundStromal reengineering to treat pancreas cancer
Stromnes, I. M., DelGiorno, K. E., Greenberg, P. D., & Hingorani, S. R. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu115 · Cited by 120
The complex landscape of pancreatic cancer metabolism
Sousa, C. M., & Kimmelman, A. C. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu097 · Cited by 120
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Pérez-Guijarro, E., Yang, H. H., Araya, R. E., El Meskini, R., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0818-3 · Cited by 118
Huang, L., Desai, R., Conrad, D. N., Leite, N. C., Akshinthala, D., Lim, C. M., González, R. S., Muthuswamy, L. B., Gartner, Z. J., & Muthuswamy, S. K. (2021) · Cell stem cell · doi:10.1016/j.stem.2021.03.022 · Cited by 133
Cell of origin influences pancreatic cancer subtype
Flowers, B. M., Xu, H., Mulligan, A. S., Hanson, K. J., Seoane, J. A., Vogel, H., Curtis, C., Wood, L. D., & Attardi, L. D. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0633 · Cited by 118
Loncle, C., Bonjoch, L., Folch‐Puy, E., López‐Millán, B., Lac, S., Molejon, M. I., Chuluyán, E., Cordelier, P., Dubus, P. R., Lomberk, G. A., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0896 · Cited by 123
“Material and Methods Mice Descriptions of the relevant strains Pdx1-cre;LSL-Kras, Pdx1-cre;LSL-Kras;Ink4a/Arf, and REG3β can be found elsewhere (31-33).”
BackgroundPhan, V. T., Wu, X., Cheng, J. H., Sheng, R. X., Chung, A. S., Zhuang, G., Tran, C., Song, Q., Kowanetz, M., Sambrone, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303302110 · Cited by 116
“MEK Inhibition Markedly Reduces G-CSF Release in a Kras-Driven GEMM.”
BackgroundMethodInfluential
Metadata
- Authors
- Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Abramson Cancer Center (US)
- Brigham and Women's Hospital (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2003-01-01
- Volume
- 17
- Issue
- 24
- Pages
- 3112-3126
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC305262
- OpenAlex
- W2126663928
- Cited by
- 1,033
- References
- 84
- Citations by year
- 2026: 16 · 2025: 27 · 2024: 38 · 2023: 34 · 2022: 40 · 2021: 67 · 2020: 46 · 2019: 45 · 2018: 46 · 2017: 55 · 2016: 49 · 2015: 63 · 2014: 69 · 2013: 67 · 2012: 53
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Lustgarten Foundation
- Dana-Farber Cancer Institute
- Barr Foundation
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- pancreatic ductal adenocarcinoma, KRAS G12D, Ink4a/Arf, tumor suppressor inactivation, pancreatic intraepithelial neoplasia, premalignant pancreatic lesions, metastasis, mouse tumor model, tumor progression, stromal cell proliferation
- MeSH terms
- Animals, Fibroblasts, Humans, Mice, Transgenic, Pancreatic Neoplasms, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Viral Proteins, Tumor Suppressor Protein p53, Mice, Knockout, Integrases, Cyclin-Dependent Kinase Inhibitor p16, Carcinoma, Pancreatic Ductal, Tumor Suppressor Protein p14ARF, Vascular Endothelial Growth Factor A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.